Perturbation of the Mutated EGFR Interactome Identifies Vulnerabilities and Resistance Mechanisms
Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB
Molecular Systems Biology; November 2013, 9: 705, available at http://www.ncbi.nlm.nih.gov/pubmed/24189400
Affinity Purification Strategies for Proteomic Analysis of Transcription Factor Complexes
Giambruno R, Grebien F, Stukalov A, Knoll C, Planyavsky M, Rudashevskaya EL, Colinge J, Superti-Furga G, Bennett KL
Journal of proteome research; September 2013, 12(9): 4018–27, available at http://www.ncbi.nlm.nih.gov/pubmed/23937658
Systems-Pharmacology Dissection of a Drug Synergy in Imatinib-Resistant CML
Winter GE, Rix U, Carlson SM, Gleixner K V, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G
Nature chemical biology; November 2012, 8(11): 905–12, available at http://www.ncbi.nlm.nih.gov/pubmed/23023260
The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL
Hantschel O, Grebien F, Superti-Furga G
Cancer research; October 2012, 72(19): 4890–95, available at http://www.ncbi.nlm.nih.gov/pubmed/23002203
Optimisation of Downscaled Tandem Affinity Purifications to Identify Core Protein Complexes
Haura EB, Sacco R, Li J, Müller AC, Grebien F, Superti-Furga G, Bennett KL
Journal of integrated OMICS; May 2012, 2(1): 55–68, available at http://www.ncbi.nlm.nih.gov/pubmed/24077984
BCR-ABL Uncouples Canonical JAK2-STAT5 Signaling in Chronic Myeloid Leukemia
Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner K-U, Superti-Furga G, Sexl V
Nature chemical biology; January 2012, 8(3): 285–93, available at http://www.ncbi.nlm.nih.gov/pubmed/22286129
Targeting Allosteric Regulatory Modules in Oncoproteins: “Drugging the Undruggable”
Hantschel O, Grebien F, Superti-Furga G
Oncotarget; November 2011, 2(11): 828–29, available at http://www.ncbi.nlm.nih.gov/pubmed/22084171
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G
Cell; October 2011, 147(2): 306–19, available at http://www.ncbi.nlm.nih.gov/pubmed/22000011
Using ITRAQ Combined with Tandem Affinity Purification to Enhance Low-Abundance Proteins Associated with Somatically Mutated EGFR Core Complexes in Lung Cancer
Haura EB, Müller A, Breitwieser FP, Li J, Grebien F, Colinge J, Bennett KL
Journal of proteome research; January 2011, 10(1): 182–90, available at http://www.ncbi.nlm.nih.gov/pubmed/20945942
CD14 Is a Coreceptor of Toll-like Receptors 7 and 9
Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Blüml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, Bennett KL, Colinge J, Knapp S, Superti-Furga G
The Journal of experimental medicine; November 2010, 207(12): 2689–2701, available at http://www.ncbi.nlm.nih.gov/pubmed/21078886
A Potent and Highly Specific FN3 Monobody Inhibitor of the Abl SH2 Domain
Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S
Nature structural & molecular biology; April 2010, 17(4): 519–27, available at http://www.ncbi.nlm.nih.gov/pubmed/20357770
Stat5 Is Indispensable for the Maintenance of Bcr/Abl-Positive Leukaemia
Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V
EMBO molecular medicine; March 2010, 2(3): 98–110, available at http://www.ncbi.nlm.nih.gov/pubmed/20201032
Stat5 Regulates Cellular Iron Uptake of Erythroid Cells via IRP-2 and TfR-1
Kerenyi MA, Grebien F, Gehart H, Schifrer M, Artaker M, Kovacic B, Beug H, Moriggl R, Müllner EW
Blood; November 2008, 112(9): 3878–88, available at http://www.ncbi.nlm.nih.gov/pubmed/18694996
Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation
Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, Neudecker P, Kay LE, Turk BE, Superti-Furga G, Pawson T, Knapp S
Cell; September 2008, 134(5): 793–803, available at http://www.ncbi.nlm.nih.gov/pubmed/18775312
Stat5 Activation Enables Erythropoiesis in the Absence of EpoR and Jak2
Grebien F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, Pfeffer K, Klingmüller U, Müller M, Beug H, Müllner EW, Moriggl R
Blood; May 2008, 111(9): 4511–22, available at http://www.ncbi.nlm.nih.gov/pubmed/18239084
The Different Functions of Stat5 and Chromatin Alteration through Stat5 Proteins
Kornfeld JW, Grebien F, Kerenyi MA, Friedbichler K, Kovacic B, Zankl B, Hoelbl A, Nivarti H, Beug H, Sexl V, Muller M, Kenner L, Mullner EW, Gouilleux F, Moriggl R
Frontiers in Bioscience; May 2008, (13): 6237–54, available at http://www.ncbi.nlm.nih.gov/pubmed/18508657
Erythroid Progenitor Renewal versus Differentiation: Genetic Evidence for Cell Autonomous, Essential Functions of EpoR, Stat5 and the GR
Dolznig H, Grebien F, Deiner EM, Stangl K, Kolbus A, Habermann B, Kerenyi MA, Kieslinger M, Moriggl R, Beug H, Müllner EW
Oncogene; May 2006, 25(20): 2890–2900, available at http://www.ncbi.nlm.nih.gov/pubmed/16407844
Cell Size Control: New Evidence for a General Mechanism
Grebien F, Dolznig H, Beug H, Mullner EW
Cell cycle (Georgetown, Tex.); March 2005, 4(3): 418–21, available at http://www.ncbi.nlm.nih.gov/pubmed/15703475
Evidence for a Size-Sensing Mechanism in Animal Cells
Dolznig Helmut, Grebien F, Sauer T, Beug H, Müllner EW
Nature cell biology; September 2004, 6(9): 899–905, available at http://www.ncbi.nlm.nih.gov/pubmed/15322555
The Grebien Group 